Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 226

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 226
---
 to Clearwater that would be more than de        
 minimis;                                                                                                                                                                                                                                                 |

| • |     | the representations and warranties of Enfusion relating to absence of changes being true and correct in all 
 respects on the Closing Date as if made on the Closing Date;                                                |

| • |     | the other representations and warranties of Enfusion being true and correct on the Closing Date as if made on the                                                                            
 Closing Date (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty will be true and correct |

140

| only as of such earlier date), except where the failure of such representations and warranties to be so true and correct (disregarding all qualifications or limitations as to 
 “materiality,” “Enfusion Material Adverse Effect” or words of similar import) would not, individually or in the aggregate, have a Enfusion Material Adverse Effect;            |

| • |     | Enfusion having performed or complied in all material respects with all obligations required to be performed or 
 complied with by it under the Merger Agreement at or prior to the Closing;                                      |

| • |     | the receipt by Clearwater of a certificate of Enfusion, signed on behalf of Enfusion by an authorized officer of                         
 Enfusion, certifying that the foregoing conditions to the obligations of the Buyer Parties to consummate the Merger have been satisfied; |

| • |     | no Burdensome Condition will be a condition to the receipt of Regulatory Approval; |

| • |     | no order or applicable law resulting, individually or in the aggregate, in a Burdensome Condition will be in 
 effect at or upon the Closing;                                                                               |

| • |     | no Regulatory Approval contains, includes or imposes any Burdensome Condition; and |

| • |     | the TRA Amendment is in full force and effected in accordance with the terms therein. |

A “ Burdensome Condition” means any restrictions, conditions, restraints or concessions with respect to the assets, properties or businesses of (i) Enfusion or its subsidiaries which would, individually or in the aggregate, result in, or be reasonably likely to result in, a material adverse effect on Enfusion and its subsidiaries, taken as a whole, (ii) Clearwater or any of its affiliates (other than, for purposes of this clause (ii), Clearwater or any of its subsidiaries (which will be subject to clause (iii) of this definition) or, following the Closing